In February 2018 FDA approved some label changes for Rexulti for the addition of warnings about pathological gambling and other compulsive behaviors. Here is some of the text which was added to the Warnings and Precautions section of the Rexulti drug label: 5.7 Pathological Gambling and Other Compulsive Behaviors Post-marketing case reports … [Read more...]
Settlements Reached for First Round of Abilify Gambling Lawsuits
Background In May 2016, the U.S. Food and Drug Administration (FDA) released a Drug Safety Communication concerning the antipsychotic drugs, Abilify, Abilify Maintena, and Aristada. This safety announcement provided the following warning: The U.S. Food and Drug Administration (FDA) is warning that compulsive or uncontrollable urges to gamble, … [Read more...]